Social and health policy; pharmaceutical policy; innovation policy; science and technology studies; political economy; history of economic thought
|Phone:||613-520-2600 x 1690|
|Office:||5201 Richcraft Hall|
Teaching Concentrations: Policy Analysis, Innovation, Science and Environment
Courses Taught: Introduction to State and Society, Social Policy, Pharmaceutical Policy, History of Economic Thought (at Kroeger College)
Areas of Expertise
- Social and Health Policy
- Political Economy and History of Economic Thought
- Pharmaceutical Policy and Regulation
- Science and Technology Studies
- Innovation policy and Intellectual Property
My empirical research focuses mainly on the political economy of the pharmaceutical sector. I analyze the dominant business models at work in the knowledge-based economy, innovation policies and intellectual property in Canada, corporate influence over scientific research and over doctors’ prescribing habits, as well as comparative regimes of health insurance and Pharmacare..
From a more theoretical standpoint relating to economic thought, my research analyzes capital accumulation and corporate competition from an institutional economics approach. I analyze capital not in terms of productivity or as “means of production” but, instead, as any socio-political power increasing firms’ earning-capacity. From this perspective, firms capitalize not only their productive capacity but also their capacities and their business network powers to influence laws, public policies, culture and socio-institutional settings in order to accrue monopolistic differential gains.
I hold a PhD in Political Science from York University and a Masters of Advanced Study in History of Economic Thought from Paris-1 Sorbonne and Ecole Normale Superieure de Fontenay/St-Cloud. I did my post-doc with the Centre for Intellectual Property Policy at McGill University’s Faculty of Law, and with the Edmond J. Safra Center for Ethics at Harvard University.
Refereed Journal Articles
- “New Drug Prices; Does it Make Any Sense?”. Prescrire International, 24 (162), July 2015: 192-195. (Version française disponible ici)
- O’Brady, Sean, Marc-André Gagnon and Alan Cassels. « Reforming Private Drug Coverage in Canada; Inefficient Drug Benefit Design and the Barriers to Change in Unionized Settings ». Health Policy, Vol. 119 #2, February 2015: 224-31
- Lexchin, Joel and Marc-André Gagnon. « CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs ». Globalization and Health, Vol. 10 #30, May 2014.
- “Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health,” in Journal of Law, Medicine and Ethics, Vol. 41 #3, September 2013: 571-580. Draft version available here.
- “Marx’s Social Analysis of Value and Big Pharma: Rethinking the Social Determinants of Value in Cognitive Capitalism.” European Journal of Economic and Social Systems 24 (1-2): 119-136.
- “Corporate influence over clinical research: Considering the alternatives” in Prescrire International, Vol. 21 #129, July 2012: pp.191-194.
- “Drug Shortages : Searching for a Cure” in Healthcare Policy, Vol. 7 (4), May 2012: pp.10-17.
- “L’aide publique à l’industrie pharmaceutique québécoise : le jeu en vaut-il la chandelle?” in Interventions Économiques / Papers in Political Economy. #44, May 2012.
- “Le modèle de croissance anglo-saxon en théorie et en pratique; Analyse du régime de croissance américain”, Cahiers de recherche sociologique, #45, February 2008: 93-111.
- Marc-André Gagnon and Joel Lexchin, “The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States”, PLoS Medicine, vol. 5, #1, January 2008: pp.1-6.
- “Capital, Power & Knowledge according to Thorstein Veblen; Reinterpreting the Knowledge-Based Economy.” Journal of Economic Issues, vol.41 #2, June 2007: 593-600.
- “Penser le capitalisme cognitif selon Thorstein Veblen; Connaissance, pouvoir & capital”, Interventions économiques, # 36, October 2007.
- Marc-André Gagnon (principal author) and Dimitri della Faille, “La sociologie économique de Thorstein Veblen; pertinences et impertinences d’une pensée à contre-courant”, Interventions économiques, # 36, October 2007.
- “Frank Zappa: Présentation d’un Intellectuel Spécifique.” Conjonctures (29), 1999: 118-145.
- The Nature of Capital in the Knowledge-Based Economy: The Case of the Global Pharmaceutical Industry. York University (political science), 2009.
- Marc-André Gagnon and Sidney Wolfe. 2015. Mirror, Mirror on the Wall: Medicare Part D pays needlessly high brand-name drug prices compared with other OECD countries and with U.S. government programs. Ottawa/Washington: Carleton University/Public Citizen.
- S.G. Morgan, D. Martin, M.-A. Gagnon, B. Mintzes, J. Daw and J. Lexchin, The Future of Drug Coverage in Canada. Vancouver: Pharmaceutical Policy Research Collaboration. July 2015.
- A Roadmap to Rational Pharmacare Policy in Canada. Ottawa: Canadian Federation of Nurses Unions. August 2014. (Version française disponible ici)
- Marie-Claude Prémont and Marc-André Gagnon. Les nouvelles stratégies commerciales de maximisation des ventes des fabricants de médicaments novateurs. Internal Report prepared for Ordre des pharmaciens du Québec. March 10, 2014.
- Marc-André Gagnonand Joel Lexchin. CETA and Pharmaceuticals: Impact of the free-trade agreement between Europe and Canada on the costs of patented drugs. Study published by the Canadian Center for Policy Alternatives. October 31 2013: https://www.policyalternatives.ca/publications/reports/ceta-and-pharmaceuticals
- Marc-André Gagnon (principal author) with the collaboration of Guillaume Hébert. The Economic Case for Universal Pharmacare. Ottawa: Canadian Health Coalition, IRIS and CCPA, September 2010.
Recent Media Coverage
- Carleton Newsroom Media Releases
- Marc-André Gagnon on The Huffington Post Blog: “what my critics don’t get about Drug Policy”
- SPPA Professor, Marc-André Gagnon speaks on how “Pharmaceutical profits increase while innovation stagnates.”
- SPPA Professor Marc-André Gagnon writes in the Winnipeg Free Press on “Patent protection for drugs should come at a price”
- Prof. Marc-André Gagnon published an op-ed on the role of ghost writers in medical research and the complacency of universities
- Marc-André Gagnon on YouTube